Track record · closed signal

Merck & Company Inc. (MRK) — closed signal from June 23, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 21, 2026 — +26.9% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$112.67 – $117.61Entry zone — fair-value band

$117.81Published — price the day we called it

$126.49Target — the price the thesis aimed for

$156.00Peak — highest point inside the window, not a realized return

$149.50Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 3 days.

At window close

+26.9%

realized, from the publication price to the last close inside the window

Peak gain

+32.4%

peak, from the publication price — not a realized return

S&P 500, same window

+5.7%

SPY over the identical days, dividend-adjusted

Window close

$149.50

last close inside the window, ended September 21, 2026

Peak price

$156.00

peak on August 25, 2026 — not a realized return

Days to target

The thesis — published June 23, 2026

Predicted growth

+8%

over the measurement window

Target price

$126.49

the price the thesis aimed for

Entry zone

$112.67 – $117.61

the fair-value band we waited for

Price at publication

$117.81

published June 23, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is seen as a defensive pick with clear regulatory wins for its cancer drug KEYTRUDA, another oncology drug, and a vaccine. These approvals give real reasons the stock could move higher, and the share price tends to be less volatile. However, recent profit trends are mixed and the stock hasn't fallen far, so short-term upside looks real but modest.

Primary drivers

FDA approvals give near-term support for the stock
KEYTRUDA and vaccines remain central revenue sources
Lower price swings help in volatile markets
Irregular earnings growth limits how high it can run

How it played out

MRK: target reached in 3 days

On June 23, Lyra published a short-term thesis at 117.81, expecting 8% growth toward 126.49. The thesis pointed to regulatory approvals for KEYTRUDA, another oncology drug, and a vaccine, plus the importance of KEYTRUDA and vaccines to revenue. It also cited lower price swings and mixed profit trends as limits on the upside.

The stock reached the target in 3 days. It later peaked at 156 on August 25, a 32.4% gain from publication. It ended the window at 149.50 on September 21, still above the target and below its peak. The published short-term thesis played out and was exceeded by the price move.

What happened during the window

On August 4, Merck reported second-quarter worldwide sales of $16.6 billion and raised and narrowed its full-year sales outlook. On August 19, Merck and Moderna announced that their Phase 3 melanoma trial of intismeran with KEYTRUDA met its recurrence-free survival and distant metastasis-free survival endpoints.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals